| Dr Sonia Sharma, DO | |
|
1221 N Highland Ave, Aurora, IL 60506-1404 | |
| (630) 859-8700 | |
| Not Available |
| Full Name | Dr Sonia Sharma |
|---|---|
| Gender | Female |
| Speciality | Hospitalist |
| Experience | 17 Years |
| Location | 1221 N Highland Ave, Aurora, Illinois |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1194981563 | NPI | - | NPPES |
| 036124542 | Medicaid | IL | |
| 04515143 | Other | IL | BCBS# |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208M00000X | Hospitalist | 036.124542 (Illinois) | Primary |
| 207R00000X | Internal Medicine | 036124542 (Illinois) | Secondary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Copley Memorial Hospital | Aurora, IL | Hospital |
| Presence Mercy Medical Center | Aurora, IL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Advocate Health And Hospitals Corporation | 7810800935 | 2422 |
News Archive
The Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology today announced the availability of a comprehensive genetic diagnostic test for inherited eye diseases.
Patient Home Monitoring, a new company focused on in-home cardiology healthcare services, today released its post Reverse Take Over third quarter financial results, which primarily represent the period from the RTO on June 2, 2010 to June 30, 2010.
Federal officials will not block insurance companies from again using a workaround to cushion a steep rise in health premiums caused by President Donald Trump's cancellation of a program established under the Affordable Care Act, Health and Human Services Secretary Alex Azar announced Wednesday.
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
Researchers at the Vienna BioCenter designed a testing protocol for SARS-CoV-2 that can process tens of thousands of samples in less than 48 hours. The method, called SARSeq, is published in the journal Nature Communications and could be adapted to many more pathogens.
› Verified 7 days ago
| Entity Name | Advocate Health And Hospitals Corporation |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1003542184 PECOS PAC ID: 7810800935 Enrollment ID: O20220930002728 |
News Archive
The Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology today announced the availability of a comprehensive genetic diagnostic test for inherited eye diseases.
Patient Home Monitoring, a new company focused on in-home cardiology healthcare services, today released its post Reverse Take Over third quarter financial results, which primarily represent the period from the RTO on June 2, 2010 to June 30, 2010.
Federal officials will not block insurance companies from again using a workaround to cushion a steep rise in health premiums caused by President Donald Trump's cancellation of a program established under the Affordable Care Act, Health and Human Services Secretary Alex Azar announced Wednesday.
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
Researchers at the Vienna BioCenter designed a testing protocol for SARS-CoV-2 that can process tens of thousands of samples in less than 48 hours. The method, called SARSeq, is published in the journal Nature Communications and could be adapted to many more pathogens.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sonia Sharma, DO 2357 Sequoia Dr, Aurora, IL 60506-6222 Ph: (630) 859-6800 | Dr Sonia Sharma, DO 1221 N Highland Ave, Aurora, IL 60506-1404 Ph: (630) 859-8700 |
News Archive
The Massachusetts Eye and Ear/Harvard Medical School Department of Ophthalmology today announced the availability of a comprehensive genetic diagnostic test for inherited eye diseases.
Patient Home Monitoring, a new company focused on in-home cardiology healthcare services, today released its post Reverse Take Over third quarter financial results, which primarily represent the period from the RTO on June 2, 2010 to June 30, 2010.
Federal officials will not block insurance companies from again using a workaround to cushion a steep rise in health premiums caused by President Donald Trump's cancellation of a program established under the Affordable Care Act, Health and Human Services Secretary Alex Azar announced Wednesday.
Visterra, Inc., a developer of novel antibody therapeutics to prevent and treat major infectious diseases, today announced that it has secured an exclusive patent license from Massachusetts Institute of Technology to a family of early-stage monoclonal antibodies that target dengue virus. These antibodies were developed by MIT in the laboratory of Dr. Ram Sasisekharan, a founder of Visterra, using novel protein engineering approaches. Visterra will apply its proprietary network analysis technology to develop a human monoclonal antibody product candidate capable of broadly neutralizing all four dengue virus serotypes.
Researchers at the Vienna BioCenter designed a testing protocol for SARS-CoV-2 that can process tens of thousands of samples in less than 48 hours. The method, called SARSeq, is published in the journal Nature Communications and could be adapted to many more pathogens.
› Verified 7 days ago
Lariven Beltran Franada, D.O. Hospitalist Medicare: Medicare Enrolled Practice Location: 1221 N Highland Ave, Aurora, IL 60506 Phone: 630-859-8700 | |
Tommy Pacana, M.D. Hospitalist Medicare: May Accept Medicare Assignments Practice Location: 1256 Waterford Dr, Suite 120, Aurora, IL 60504 Phone: 630-499-6688 | |
Lisa A Groskopf, DO Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1221 N Highland Ave, Aurora, IL 60506 Phone: 630-801-2678 | |
Brenda K. Fann, MD Hospitalist Medicare: May Accept Medicare Assignments Practice Location: 2020 Ogden Ave, Suite 330, Aurora, IL 60504 Phone: 630-978-4850 Fax: 630-978-6865 | |
Zia Samad, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1325 N Highland Ave, Aurora, IL 60506 Phone: 630-801-2059 | |
Ryoko Noguchi, Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 1325 N Highland Ave, Aurora, IL 60506 Phone: 630-859-2222 |